EB05の新興薬剤に関する洞察と市場予測：2032年

当レポートでは、主要7ヶ国におけるEB05市場について調査し、市場の概要とともに、2025年から2032年までの売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 急性呼吸窮迫症候群におけるEB05の概要

• 製品の詳細
• 臨床開発
  • 臨床試験
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（後期段階の新興治療法）

第4章 EB05市場評価

• 急性呼吸窮迫症候群に対するEB05の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における急性呼吸窮迫症候群に対するEB05の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

• 参考文献
• レポートの調査手法

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: EB05, Clinical Trial Description, 2022
• Table 2: EB05, General Description, 2022
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: EB05 Market Size in the 7MM, in USD million (2019-2032)
• Table 5: EB05 Market Size in the US, in USD million (2019-2032)
• Table 6: EB05 Market Size in Germany, in USD million (2019-2032)
• Table 7: EB05 Market Size in France, in USD million (2019-2032)
• Table 8: EB05 Market Size in Italy, in USD million (2019-2032)
• Table 9: EB05 Market Size in Spain, in USD million (2019-2032)
• Table 10: EB05 Market Size in the UK, in USD million (2019-2032)
• Table 11: EB05 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: EB05 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: EB05 Market Size in the United States, USD million (2019-2032)
• Figure 3: EB05 Market Size in Germany, USD million (2019-2032)
• Figure 4: EB05 Market Size in France, USD million (2019-2032)
• Figure 5: EB05 Market Size in Italy, USD million (2019-2032)
• Figure 6: EB05 Market Size in Spain, USD million (2019-2032)
• Figure 7: EB05 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: EB05 Market Size in Japan, USD million (2019-2032)

"EB05 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about EB05 for Acute Respiratory Distress Syndrome in seven major markets. A detailed picture of the EB05 for Acute Respiratory Distress Syndrome in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the EB05 for Acute Respiratory Distress Syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EB05 market forecast analysis for Acute Respiratory Distress Syndrome in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Acute Respiratory Distress Syndrome.

Drug Summary:

EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with ARDS. Specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling - an important mediator of inflammation responsible for acute lung injury that is activated by SARS-CoV2, SARS-CoV1, and Influenza viruses.

The company received approval from Health Canada to test EB05 as a rescue therapy for critically ill patients in the Phase III part of a Phase II/III clinical study. Approval of the company's Phase III study design followed favorable Phase II results, which demonstrated compelling preliminary evidence of EB05's ability to reduce mortality in the sickest patients. Edesa has filed similar protocol amendments with the US FDA as well as other jurisdictions. In the US, the company is currently in discussions with the FDA on the design of the final Phase III protocol.

The company is also developing an EB06 monoclonal antibody in Phase II for the treatment of ARDS according to the company's pipeline. It acts by inhibiting the signaling protein CXCL10.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the EB05 description, mechanism of action, dosage and administration, research and development activities in Acute Respiratory Distress Syndrome.
• Elaborated details on EB05 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EB05 research and development activities in Acute Respiratory Distress Syndrome across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around EB05.
• The report contains forecasted sales of EB05 for Acute Respiratory Distress Syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Acute Respiratory Distress Syndrome.
• The report also features the SWOT analysis with analyst views for EB05 in Acute Respiratory Distress Syndrome.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EB05 Analytical Perspective by DelveInsight

• In-depth EB05 Market Assessment

This report provides a detailed market assessment of EB05 for Acute Respiratory Distress Syndrome in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• EB05 Clinical Assessment

The report provides the clinical trials information of EB05 for Acute Respiratory Distress Syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Acute Respiratory Distress Syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EB05 dominance.
• Other emerging products for Acute Respiratory Distress Syndrome are expected to give tough market competition to EB05 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EB05 in Acute Respiratory Distress Syndrome.
• Our in-depth analysis of the forecasted sales data of EB05 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EB05 in Acute Respiratory Distress Syndrome.

Key Questions

• What is the product type, route of administration and mechanism of action of EB05?
• What is the clinical trial status of the study related to EB05 in Acute Respiratory Distress Syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EB05 development?
• What are the key designations that have been granted to EB05 for Acute Respiratory Distress Syndrome?
• What is the forecasted market scenario of EB05 for Acute Respiratory Distress Syndrome?
• What are the forecasted sales of EB05 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to EB05 for Acute Respiratory Distress Syndrome?
• Which are the late-stage emerging therapies under development for the treatment of Acute Respiratory Distress Syndrome?

Table of Contents

1. Report Introduction

2. EB05 Overview in Acute Respiratory Distress Syndrome

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical Studies
  • 2.2.2. Clinical Trials Information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. EB05 Market Assessment

• 4.1. Market Outlook of EB05 in Acute Respiratory Distress Syndrome
• 4.2. 7MM Market Analysis
  • 4.2.1. Market Size of EB05 in the 7MM for Acute Respiratory Distress Syndrome
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market Size of EB05 in the United States for Acute Respiratory Distress Syndrome
  • 4.3.2. Market Size of EB05 in Germany for Acute Respiratory Distress Syndrome
  • 4.3.3. Market Size of EB05 in France for Acute Respiratory Distress Syndrome
  • 4.3.4. Market Size of EB05 in Italy for Acute Respiratory Distress Syndrome
  • 4.3.5. Market Size of EB05 in Spain for Acute Respiratory Distress Syndrome
  • 4.3.6. Market Size of EB05 in the United Kingdom for Acute Respiratory Distress Syndrome
  • 4.3.7. Market Size of EB05 in Japan for Acute Respiratory Distress Syndrome

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options